Skip to content

Prevalence, Clinical Features and Risk Factors of Cirrhotic Cardiomyopathy Assessed by Two-dimensional Speckle Tracking Imaging

Prevalence, Clinical Features and Risk Factors of Cirrhotic Cardiomyopathy Assessed by Two-dimensional Speckle Tracking Imaging

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04969055
Enrollment
200
Registered
2021-07-20
Start date
2020-11-01
Completion date
2022-07-31
Last updated
2022-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cirrhotic Cardiomyopathy, Liver Cirrhosis

Keywords

Cirrhosis; cardiac dysfunction;Cardiac Imaging

Brief summary

The purpose of this study is to assess the prevalence of cirrhotic cardiomyopathy in patients with cirrhosis, and to analyze the correlation between the severity of cirrhosis and cardiac dysfunction. To investigate the risk factors for cirrhotic cardiomyopathy, and raise clinicians' awareness of cirrhotic cardiomyopathy, early assessment and intervention to improve long-term outcomes in patients with cirrhosis.

Detailed description

Liver cirrhosis is the terminal stage of the development of chronic liver disease caused by various reasons, and it is often accompanied by multiple complications. Late cirrhosis is often accompanied by obvious changes in liver and systemic hemodynamics. Patients with liver cirrhosis are in a highly dynamic cycle Status: lower arterial blood pressure, increased heart rate, increased cardiac output, peripheral vascular resistance, which often lead to changes in myocardial structure and function, called cirrhotic cardiomyopathy. Cirrhotic cardiomyopathy (CCM) is defined as cardiac dysfunction in patients with end-stage liver disease in the absence of prior heart disease. The true burden of CCM among patients with ESLD is currently unknown. Prior studies evaluated CCM prevalence and estimated it to be approximately 50%, however, this estimate was based on the old criteria. In 2020, the Cirrhotic Cardiomyopathy Association updated the diagnostic criteria for cirrhotic cardiomyopathy. At present, the true prevalence of cirrhotic cardiomyopathy still needs to be reassessed. In addition, studies on the risk factors for cirrhotic cardiomyopathy are rare. Based on the above research background, carry out this research.

Interventions

OTHERNot

Not

Sponsors

Qilu Hospital of Shandong University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* The clear diagnosis of cirrhosis in patients caused by various reasons

Exclusion criteria

* History of cardiovascular disease * Diabetes * High blood pressure * Hepatocellular carcinoma (HCC) or other malignant tumors * Patients with the chronic obstructive pulmonary disease * Thyroid diseases * Severe infection in the last 2 weeks * History of liver transplantation and/or TIPS surgery * Presence of stage 3 or above chronic kidney disease or acute chronic kidney disease * Pregnant women * Did not sign the informed consent form and refused to participate

Design outcomes

Primary

MeasureTime frameDescription
cirrhotic cardiomyopathyWithin 48 hours after hospitalizationDifferent levels of left ventricular diastolic dysfunction in patients with liver cirrhosis

Other

MeasureTime frameDescription
N-terminal Pro-brain Natriuretic Peptide serum levelWithin 48 hours after hospitalizationVenous blood sampling was performed in the morning, after a 12-h fast. serum levels of NT-proBNP were measured by an electrochemiluminescence immunoassay.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026